Fig. 4: FGF21 decreases PDK4 expression in mice with HFpEF.
From: FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice
A Volcano plot of proteomic analysis in AAV-Fgf21- or AAV-GFP-treated mice with HFpEF. B Heatmap of the differentially expression proteins (DEPs) in the heart tissues of AAV-Fgf21- or AAV-GFP-treated mice with HFpEF. C Relative expression levels of cardiac PDK4 in AAV-Fgf21- or AAV-GFP-treated mice with HFpEF from the proteomic analysis data. n = 4 mice per condition. Cardiac PDK4 levels in Fgf21 KO and WT mice with or without HFpEF (D) or AAV-Fgf21- or AAV-GFP-treated HFpEF mice (E), tested by immunoblot, respectively. n = 6 mice per condition. The expressional difference of cardiac PDK4 in the mitochondria (F) and non-mitochondria (G) of cardiomyocytes in HFpEF mice and controls was examined by immunoblot, respectively. n = 6 mice per condition. Data are presented as mean ± SEM. Statistical significance was determined by the two-tailed unpaired Student’s t test (A, F, G), two-sided Brown-Forsythe and Welch ANOVA with Dunnett’s multiple comparison test (C), or two-way ANOVA with Tukey’s multiple comparison test (D, E).
